Drug Approval | September 19, 2024
Lupin receives USFDA approval for Bumetanide Injection
Bumetanide Injection USP (RLD Bumex) had estimated annual sales of USD 20 million in the U.S.
Bumetanide Injection USP (RLD Bumex) had estimated annual sales of USD 20 million in the U.S.
Finerenone significantly reduced the composite of cardiovascular death and total (first and recurrent) heart failure events compared to placebo in addition to usual therapy
Decision on EU marketing authorisation for this population expected by September 2024
The drug will be manufactured at the group's formulation manufacturing facility in Ahmedabad SEZ - II, India
Sacubitril and Valsartan combination is used to treat chronic heart failure in adults
Over 13 million US adults aged 50-59 years have a medical condition that increases their risk of severe RSV outcomes
Sacubitril and Valsartan Tablets are indicated to reduce the risk of cardiovascular death
Vericiguat works on a pathway not currently targeted by existing heart failure treatments
TriClip offers a remarkably safe, minimally invasive treatment option for patients in need of tricuspid valve repair but who are unable to withstand surgery
Acquisition of exclusive commercialization rights for European markets
Subscribe To Our Newsletter & Stay Updated
